Adoptive transfer of FTY720-treated immature BMDCs significantly prolonged cardiac allograft survival

Transplant International

Volumn 23, Issue 12, 2010, Pages 1259-1270

  Heng, Yang ^a   Ma, Yuting ^a   Yin, Hui ^b   Duan, Lihua ^a   Xiong, Ping ^a   Xu, Yong ^a   Feng, Wei ^a   Fang, Min ^a   Tan, Zheng ^a   Chen, Yifa ^c   Zheng, Fang ^a   Gong, Feili ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

bone marrow derived dendritic cells; cardiac transplantation; FTY720; Treg

Indexed keywords

FINGOLIMOD; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CELL; CARDIAC GRAFT REJECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE SEVERITY; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART GRAFT; HEART TRANSPLANTATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN LYMPHOCYTE; TH1 CELL; UPREGULATION;

ADOPTIVE TRANSFER; ANIMALS; BONE MARROW CELLS; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT SURVIVAL; HEART TRANSPLANTATION; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PHAGOCYTOSIS; PROPYLENE GLYCOLS; SPHINGOSINE; T-LYMPHOCYTES, REGULATORY;

EID: 78649314115     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01119.x     Document Type: Article

References (62)

1. Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 1996; 61: 200.
2. Mitsusada M, Suzuki S, Kobayashi E, et al. Prevention of graft rejection and graft-versus-host reaction by a novel immunosuppressant, FTY720, in rat small bowel transplantation. Transpl Int 1997; 10: 343.
3. Martin M, Mory C, Prescher A, et al. Protective effects of early CD4(+) T cell reduction in hepatic ischemia/reperfusion injury. J Gastrointest Surg 2010; 14: 511.
4. Hasegawa Y, Suzuki H, Sozen T, et al. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke 2010; 41: 368.
5. Gasperini C, Ruggieri S,. New oral drugs for multiple sclerosis. Neurol Sci 2009; 30 (Suppl. 2): S179.
6. Matsuura M, Imayoshi T, Chiba K, et al. Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats. Inflamm Res 2000; 49: 404.
7. Wei SH, Rosen H, Matheu MP, et al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol 2005; 6: 1228.
8. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355.
9. Graler MH, Goetzl EJ,. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004; 18: 551.
10. Czeloth N, Schippers A, Wagner N, et al. Sphingosine-1 phosphate signaling regulates positioning of dendritic cells within the spleen. J Immunol 2007; 179: 5855.
11. Japtok L, Kleuser B,. The role of sphingosine-1-phosphate receptor modulators in the prevention of transplant rejection and autoimmune diseases. Curr Opin Investig Drugs 2009; 10: 1183.
12. Tedesco-Silva H, Pescovitz MD, Cibrik D, et al. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 2006; 82: 1689.
13. + regulatory T cells. J Immunol 2007; 178: 2458.
14. + T-regulatory cells and enhances their functional activity. J Immunol 2005; 175: 7973.
15. + regulators. J Immunol 2008; 180: 7636.
16. Wolf AM, Eller K, Zeiser R, et al. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J Immunol 2009; 183: 3751.
17. Idzko M, Hammad H, Van Nimwegen M, et al. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest 2006; 116: 2935.
18. Lan YY, Tokita D, Wang Z, et al. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival. Transpl Immunol 2008; 20: 88.
19. Lan YY, De Creus A, Colvin BL, et al. The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am J Transplant 2005; 5: 2649.
20. Hawksworth JS, Leeser D, Jindal RM, et al. New directions for induction immunosuppression strategy in solid organ transplantation. Am J Surg 2009; 197: 515.
21. Lu L, Woo J, Rao AS, et al. Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med 1994; 179: 1823.
22. Zhang X, Li M, Lian D, et al. Generation of therapeutic dendritic cells and regulatory T cells for preventing allogeneic cardiac graft rejection. Clin Immunol 2008; 127: 313.
23. Darrasse-Jeze G, Deroubaix S, Mouquet H, et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med 2009; 206: 1853.
24. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8.
25. Turnquist HR, Fischer RT, Thomson AW, Pharmacological modification of dendritic cells to promote their tolerogenicity in transplantation. Methods Mol Biol 2010; 595: 135.
26. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77.
27. Corry RJ, Winn HJ, Russell PS,. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16: 343.
28. Ma Y, Yang H, Qi J, et al. CD2AP is indispensable to multistep cytotoxic process by NK cells. Mol Immunol 2010; 47: 1074.
29. Merville P, Pouteil-Noble C, Wijdenes J, et al. Cells infiltrating rejected human kidney allografts secrete IFN-gamma, IL-6, and IL-10, and are modulated by IL-2 and IL-4. Transplant Proc 1993; 25: 111.
30. Merville P, Pouteil-Noble C, Wijdenes J, et al. Detection of single cells secreting IFN-gamma, IL-6, and IL-10 in irreversibly rejected human kidney allografts, and their modulation by IL-2 and IL-4. Transplantation 1993; 55: 639.
31. Pavlakis M, Strehlau J, Lipman M, et al. Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation 1996; 62: 543.
32. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008; 205: 3133.
33. Mitchell RN, Lichtman AH,. The link between IFN-gamma and allograft arteriopathy: is the answer NO? J Clin Invest 2004; 114: 762.
34. Koh KP, Wang Y, Yi T, et al. T cell-mediated vascular dysfunction of human allografts results from IFN-gamma dysregulation of NO synthase. J Clin Invest 2004; 114: 846.
35. Van Loosdregt J, Van Oosterhout MF, Bruggink AH, et al. The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. Circulation 2006; 114: 1599.
36. Sica GL, Choi IH, Zhu G, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003; 18: 849.
37. Prasad DV, Nguyen T, Li Z, et al. Murine B7-H3 is a negative regulator of T cells. J Immunol 2004; 173: 2500.
38. Wesa AK, Storkus WJ,. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. Cell Death Differ 2008; 15: 51.
39. Lu L, Qian S, Hershberger PA, et al. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J Immunol 1997; 158: 5676.
40. Hewitt CW, Black KS, Henson LE, et al. Lymphocyte chimerism in a full allogeneic composite tissue (rat-limb) allograft model prolonged with cyclosporine. Transplant Proc 1988; 20: 272.
41. Fontes P, Rao AS, Demetris AJ, et al. Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet 1994; 344: 151.
42. Rao AS, Fontes P, Zeevi A, et al. Enhancement of donor cell chimerism in whole organ allograft recipients by adjuvant bone marrow transplantation. Transplant Proc 1995; 27: 3387.
43. Reinsmoen NL, Jackson A, Hertz M, et al. Peripheral blood allogeneic microchimerism in lung and cardiac allograft recipients. J Leukoc Biol 1999; 66: 306.
44. Silk KM, Fairchild PJ,. Harnessing dendritic cells for the induction of transplantation tolerance. Curr Opin Organ Transplant. 2009; 14: 344.
45. + regulatory T cells including suppressors of alloreactivity. Immunol Rev 2006; 212: 314.
46. Fischer R, Turnquist HR, Taner T, et al. Use of rapamycin in the induction of tolerogenic dendritic cells. Handb Exp Pharmacol 2009; 188: 215.
47. + T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178: 7018.
48. Horibe EK, Sacks J, Unadkat J, et al. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl Immunol 2008; 18: 307.
49. Emmanouilidis N, Guo Z, Dong Y, et al. Immunosuppressive and trafficking properties of donor splenic and bone marrow dendritic cells. Transplantation 2006; 81: 455.
50. + cells. J Immunol 2006; 176: 3915.
51. Schlecht G, Mouries J, Poitrasson-Riviere M, et al. Purification of splenic dendritic cells induces maturation and capacity to stimulate Th1 response in vivo. Int Immunol 2006; 18: 445.
52. + regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003; 198: 235.
53. Thomson AW, Turnquist HR, Zahorchak AF, et al. Tolerogenic dendritic cell-regulatory T-cell interaction and the promotion of transplant tolerance. Transplantation 2009; 87: S86.
54. Zhai Y, Wang Y, Wu Z, et al. Defective alloreactive CD8 T cell function and memory response in allograft recipients in the absence of CD4 help. J Immunol 2007; 179: 4529.
55. Pietra BA, Wiseman A, Bolwerk A, et al. CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II. J Clin Invest 2000; 106: 1003.
56. Morita M, Fujino M, Jiang G, et al. PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft. Am J Transplant 2010; 10: 40.
57. Cheng X, Dai H, Wan N, et al. Interaction of programmed death-1 and programmed death-1 ligand-1 contributes to testicular immune privilege. Transplantation 2009; 87: 1778.
58. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027.
59. Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009; 10: 1185.
60. Corthay A,. How do regulatory T cells work? Scand J Immunol 2009; 70: 326.
61. Vignali DA, Collison LW, Workman CJ,. How regulatory T cells work. Nat Rev Immunol 2008; 8: 523.
62. Muller H, Hofer S, Kaneider N, et al. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 2005; 35: 533.